ACRS (Aclaris Therapeutics) Cyclically Adjusted PB Ratio: (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACRS Aclaris Therapeutics Inc ACRS
33 GF Score
Price $5.91
GF Value $0.43
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aclaris Therapeutics  (NAS:ACRS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Aclaris Therapeutics Cyclically Adjusted PB Ratio Related Terms


Aclaris Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Aclaris Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Cyclically Adjusted PB Ratio Chart

Aclaris Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.62 0.75

Aclaris Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.46 0.75 0.94 0.00

ACRS vs FTH, AURA, CLYM: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Aclaris Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Cyclically Adjusted PB Ratio falls into.


ACRS
33GF Score
Aclaris Therapeutics Inc ACRS
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aclaris Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Aclaris Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Aclaris Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.873/333.9520*333.9520
=0.873

Current CPI (Jun. 2026) = 333.9520.

Aclaris Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.787 241.428 5.238
201612 6.504 241.432 8.996
201703 6.142 243.801 8.413
201706 6.289 244.955 8.574
201709 7.921 246.819 10.717
201712 7.300 246.524 9.889
201803 6.487 249.554 8.681
201806 5.626 251.989 7.456
201809 4.722 252.439 6.247
201812 5.220 251.233 6.939
201903 4.416 254.202 5.801
201906 3.324 256.143 4.334
201909 2.061 256.759 2.681
201912 1.685 256.974 2.190
202003 1.402 258.115 1.814
202006 1.156 257.797 1.497
202009 0.950 260.280 1.219
202012 0.835 260.474 1.071
202103 2.156 264.877 2.718
202106 3.820 271.696 4.695
202109 3.537 274.310 4.306
202112 3.223 278.802 3.861
202203 2.919 287.504 3.391
202206 3.536 296.311 3.985
202209 3.297 296.808 3.710
202212 2.963 296.797 3.334
202303 2.631 301.836 2.911
202306 2.540 305.109 2.780
202309 2.208 307.789 2.396
202312 2.217 306.746 2.414
202403 1.993 312.332 2.131
202406 1.876 314.175 1.994
202409 1.822 315.301 1.930
202412 1.442 315.605 1.526
202503 1.331 319.799 1.390
202506 1.216 322.561 1.259
202509 1.109 324.800 1.140
202512 0.855 324.054 0.881
202603 1.029 330.213 1.041
202606 0.873 333.952 0.873

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $5.91 is trading 1273.3% above its estimated GF Value™ of $0.43. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $0.43 vs. price of $5.91 (1273.3% above fair value)
  • GF Score™: 33/100 with 9 warning signs

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aclaris Therapeutics Business Description

Other Exchanges 0H8T:UK8AT:Germany
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
33GF Score

Get the complete analysis for ACRS

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.91
Price
$0.43
GF Value